David Cotter is a Dermatology physician affiliated with University of Nevada. OpenAlex indexes 42 publications with 1,421 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
653 N Town Center Dr Ste 414
Las Vegas, NV 891440518
Telephone
702-456-3120Provider last certified this registry record 24 Aug 2023.
Industry payments
49 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202560 payments$110,651openpaymentsdata.cms.gov ↗
- UCB, Inc.Program year202590 payments$92,214openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year202556 payments$84,044openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
35.5%Azole Antifungal19.4%Ketoconazole100%Part D≥67 patientsTetracycline-class Drug6.5%Doxycycline Hyclate100%Part D≥31 patients+ 2 more classes in this area
Dermatology
20.3%Corticosteroid11.5%Triamcinolone Acetonide100%Part D≥66 patientsInterleukin-4 Receptor alpha Antagonist4.6%Dupixent Pen100%Part D<11 patients+ 2 more classes in this area
Sensory organs
14.4%Corticosteroid14.4%Hydrocortisone38%Clobetasol Propionate32%Betamethasone Diprop Augmented31%Part D≥27 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Pumping Up Dermatologic Drug Reformulation: A Review of How Proton Pump Inhibitors May Revolutionize Scleroderma Treatment.
PubMed
2026 - Clinical Management of Dupilumab-related Conjunctivitis, Erythema, and Arthralgia in Atopic Dermatitis: Evidence From Two Cases Treated with Nemolizumab.
PubMed
2026 - A Transient "Blueberry Muffin" Rash in a Neonate with Acute Myeloid Leukemia: A Case Report and Review of the Literature.
PubMed
2026 - The Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists in Psoriasis and Hidradenitis Suppurativa.
PubMed
2026 - Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab
Journal of Drugs in Dermatology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Buddhadeb Dawn, MD
University of Nevada
Paul Hauptman, MD
University of Nevada
Lali Sekhon, MD, PhD
University of Nevada
Abraham Rothman, MD
University of Nevada
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”